Drug
Hx575 Epoetin Alfa Hexal AG
Hx575 Epoetin Alfa Hexal AG: highest development phase Phase 3, developed by Sandoz. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sandoz
Trials
| Drug | Phase | Indication |
|---|---|---|
| HX575 epoetin alfa Hexal AG NCT00666835 | Phase 3 | Anemia |
Latest
No recent events.
Follow Hx575 Epoetin Alfa Hexal AG on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.